Abstract 6183: PARP inhibitors preferentially sensitize splicing factor mutant myeloid neoplasms
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6183
Abstract: Somatic heterozygous mutations in genes encoding for RNA splicing factors (SF) SRSF2, U2AF1, and SF3B1 are frequently mutated in patients with hematologic malignancies, representing a unique genetic vulnerability for targeted therapy. In the current study,… read more here.
Keywords: parp; srsf2p95h u2af1s34f; inhibitors preferentially; parp inhibitors ... See more keywords